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Natriuretic peptides are important in regulating salt and
body-fluid balance. In cells, these peptides are made as
precursor forms that are converted to active forms by
proteolyic processing. Corin is a transmembrane serine
protease identified in the heart. Corin converts pro-atrial
natriuretic peptide (pro-ANP) to active ANP in a
sequence-specific manner. In mice, lack of corin prevents
the conversion of pro-ANP to ANP and causes salt-sensitive
hypertension. The hypertensive phenotype is exacerbated
when the mice become pregnant. In humans, single
nucleotide polymorphisms in the corin gene have been
identified in African Americans with hypertension and cardiac
hypertrophy. These data indicate that corin is important in
maintaining normal blood pressure in vivo and that corin
deficiency may contribute to hypertension and heart disease
in patients.
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THE NATRIURETIC PEPTIDE SYSTEM
The natriuretic peptide system, which was first discovered in
the early 1980s by Adolfo de Bold,1 is an endocrine
mechanism that regulates salt and body fluid balance. The
system is conserved in all vertebrates ranging from the most
primitive species such as hagfish to humans. For many teleost
species, natriuretic peptides are critical for their adaptation to
low- and high-salt environments. Salmon and some eels, for
example, live in both fresh and salty water during different
phases of their life cycles. Natriuretic peptides have been
identified in these animals.2,3 In Japanese eel (Anguilla
japonica), natriuretic peptides are shown to be important in
controlling water drinking and regulating salt absorption and
excretion in gills, guts, and kidneys when the animals switch
between low-salt freshwater and high-salt seawater.3 Unlike
the teleost fish, terrestrial mammals do not have to deal with
constant surroundings of dangerously low or high salt.
Nevertheless, natriuretic peptides are important in maintain-
ing blood volume and electrolyte balance, as drinking water
and food contents on earth may vary dramatically in different
seasons and locations.
The mammalian natriuretic peptide family has three
structurally related members, namely atrial natriuretic
peptide (ANP) or atrial natriuretic factor, brain or B-type
natriuretic peptide (BNP), and C-type natriuretic peptide
(CNP). ANP and BNP are made primarily in the heart
whereas CNP is made in many organs including the brain,
kidney, bone, and vessels. The primary function of ANP and
BNP is to regulate blood volume and pressure. Under high
blood volume or pressure, ANP and BNP are released into the
circulation. In target organs such as kidneys and peripheral
blood vessels, the peptides activate their receptor, natriuretic
peptide receptor-A (NPR-A), and increase intracellular
cGMP production, leading to natriuresis, diuresis, and
vasodilation, and thereby lowering blood volume and
pressure. ANP and BNP also suppress renin and endothelin
release, which is an additional mechanism to regulate
vascular tone. In contrast, CNP binds to natriuretic peptide
receptor-B (NPR-B), inhibits vascular smooth muscle cell
proliferation, and prevents coronary artery restenosis in
animal models. CNP and NPR-B also have a major role in
chondrocyte differentiation and bone formation.4 There is a
third natriuretic peptide receptor, NPR-C, which binds all
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three peptides and remove them from the circulation. Several
recent articles have reviewed various aspects of the natriuretic
peptide system in depth.5–7
BIOSYNTHESIS OF NATRIURETIC PEPTIDES
Like many peptide hormones, natriuretic peptides are
synthesized as prepropeptides. After the signal peptide is
removed, an additional proteolytic cleavage is required to
convert the inactive propeptide to an active peptide
(Figure 1). This post-translational processing step represents
an important mechanism in regulating the activity of the
natriuretic peptides, but identifying the endogenous proces-
sing enzymes was challenging. Several laboratories, for
example, showed that thrombin and kellikreins could process
pro-ANP in vitro.8 However, it was difficult to prove that the
observed activities were specific and to show that these
enzymes function as the physiological pro-ANP convertase
in vivo. Other studies also indicated that a cell membrane-
associated high-molecular weight trypsin-like enzyme in the
heart may be the pro-ANP convertase, but purification of
this enzyme was unsuccessful.9 As a result, the enzymes
responsible for processing natriuretic peptides remain
undefined for many years.
THE CARDIAC SERINE PROTEASE CORIN
The discovery of corin was serendipitous. Our interests in
serine proteases started with thrombin, a blood-clotting
enzyme whose activity is greatly enhanced in the presence of
cell membranes. Later, we extended our work to include
transmembrane serine proteases such as enteropeptidase and
hepsin,10 which subsequently led us to search for other
transmembrane serine proteases in the cardiovascular system.
By searching databases for genes with trypsin-like sequences,
we cloned a new membrane serine protease from the human
heart and named it corin for its cardiac expression.11
As shown in Figure 2, corin is a mosaic protein consisting
of a transmembrane domain near the N terminus and two
frizzled-like domains, eight LDL receptor repeats, a scavenger
receptor –like domain, and a trypsin-like protease domain at
the C terminus. Such a protein domain arrangement is
unique. To date, corin remains the only known trypsin-like
protease that contains frizzled-like domains, which are
mostly associated with Wnt signaling proteins. Moreover,
human corin, as a serine protease, is exceptionally large with
1042 amino acids. There are 19 predicted N-linked
glycosylation sites in its extracellular region.11 On SDS–poly-
acrylamide gel electrophoresis and western analysis, native
and recombinant human, rat, and mouse corin proteins had
apparent molecular masses of B150–200 kDa.12–15 The
human corin gene is on chromosome 4p12–13 with 22 exons
and spans 4200 kb,16 making it one of the biggest protease
genes known to date.
Corin is made primarily in the heart. We and others
detected corin mRNA and protein in fetal and adult
cardiomyocytes.11,13 Corin mRNA expression appeared to
be higher in the atrium than the ventricle (Figure 2). Corin
mRNA was also found in scar myofibroblasts in rat hearts.17
Lower levels of corin mRNA were detected in other tissues,
including developing kidneys and bones.11 Most recently,
corin mRNA and protein were detected in mouse skin hair
follicles.18 In contrast, corin mRNA was not found in other
muscle-rich tissues, such as stomach, small intestine, bladder,
skeletal muscle, and nonpregnant uterus.11
CORIN IN PRO-ANP PROCESSING
We next set out to identify corin function. Because corin is a
cardiac transmembrane protease with trypsin-like substrate
specificity, it is likely that the corin substrate is a protein in
the heart that is cleaved at a basic amino acid. Pro-ANP,
which is made in the heart and proteolytically activated at
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Figure 1 | Processing of natriuretic peptides. Natriuretic
peptides are synthesized as prepropeptides. The signal peptide
(sp) is removed by signal peptidase. The propeptide is cleaved by
propeptide convertase to produce an inactive N-terminal peptide
and a C-terminal mature peptide that is biologically active.
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Figure 2 | Corin domain structure and mRNA expression in the
heart. Corin has a transmembrane domain (TM), two frizzled-like
domains (Fz), eight LDL receptor repeats (LDLR), a scavenger
receptor domain (SR), and a trypsin-like protease domain with
three active site amino acids His (H), Asp (D), and Ser (S). Corin
mRNA expression in the atrium and ventricle of a mouse heart at
embryonic day 15.5 was detected by in situ hybridization.
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Arg-98, could be a candidate substrate for corin. We did
biochemical and cellular studies to test this hypothesis. In
cell- and purified protein-based assays, corin converted pro-
ANP to ANP in a sequence-specific manner.15,19,20 In
cultured cardiomyocytes, overexpression of a negative
mutant corin or transfection of small interfering RNA against
the corin gene blocked pro-ANP processing,21 suggesting that
corin is the pro-ANP convertase.
To define the functional importance of corin in vivo, we
made corin-null mice and showed that atrial tissues from
these mice had pro-ANP but no ANP, indicating that
pro-ANP processing was abolished in the knockout mice.22
Infusion of a soluble corin into these mice transiently
restored pro-ANP processing, resulting in the release of active
ANP into the circulation. These results have established corin
as the physiological pro-ANP convertase and solved a long-
standing puzzle in natriuretic peptide biology.23,24 In
cell-based assays, corin also cleaved pro-BNP, although the
reaction was less efficient than that for pro-ANP.15 Previous
reports suggested that other enzymes may also process
pro-BNP.25 Further studies are needed to define the pro-BNP
convertase in vivo.
In contrast, corin did not cleave pro-CNP in similar
experiments.26 In human kidney cells and chondrocytes,
recombinant human pro-CNP was processed without corin.
Corin overexpression did not enhance pro-CNP processing
in these cells. The results are consistent with the fact that the
pro-CNP cleavage sequence differs from that in pro-ANP
and pro-BNP, and the fact that pro-CNP is processed
intracellularly, whereas corin acts extracellularly. We went
on and tested furin, a trans-Golgi enzyme, as a candidate for
pro-CNP convertase. Using furin-deficient LoVo cells and
purified recombinant furin protein, we showed that pro-CNP
is activated by furin.26 Thus, natriuretic peptides are
processed by different enzymes, although they share
significant sequence and structural similarities.
HYPERTENSION IN CORIN KNOCKOUT MICE
The ANP pathway is important in regulating blood pressure.
Knockout mice lacking ANP or NPR-A are hypertensive.27,28
If corin is essential for pro-ANP activation, mice with corin
deficiency are expected to have a similar hypertensive
phenotype. Using radiotelemetry, we found that corin-null
mice, which are viable and fertile, indeed were hypertensive.22
Both male and female corin-null mice had elevated systolic,
diastolic, and mean arterial blood pressure compared to that
in wild-type controls. Blood pressure increased further
when the mice were fed a high-salt diet. Such a phenotype
was also reported in ANP-null mice.27 The data are consistent
with corin being the pro-ANP convertase and show the
importance of corin in maintaining normal blood pressure
in vivo.
In Northern blotting, corin mRNA was found only in the
heart. By in situ hybridization, however, abundant corin
mRNA was detected in the decidual cells of the pregnant
mouse uterus.11 Corin mRNA was also found in human
endometrium and leiomyosarcoma cells.11 The finding of
uterine corin expression was unexpected but may suggest a
role of corin in pregnancy. As blood volume expands
significantly during pregnancy, maintaining normal blood
pressure becomes increasingly challenging. As a result,
additional regulations may be needed to deal with this
special condition. It is possible that the uterine corin
expression is a previously unrecognized mechanism to
prevent hypertension during pregnancy.
If this hypothesis is correct, we should expect further
blood pressure increase when corin-null mice become
pregnant. By telemetric monitoring, we indeed found a
significant increase of systolic blood pressure in pregnant
corin-null mice, which reached the highest level at
mid-gestation but eventually returned to pre-pregnancy
levels after delivery.22 The pregnant corin-null mice also
develop late-gestational proteinuria, reminiscent of
preeclampsia in patients. Histological analysis indicated
endotheliosis and ischemic changes in glomeruli in these
mice. These results suggest that corin may be exploited
during pregnancy to regulate hemodynamic changes and
prevent hypertension. Corin-null mice may be used as a new
model of preeclampsia.
HUMAN CORIN VARIANTS AND HYPERTENSION
Single nucleotide polymorphisms (SNPs) in the ANP gene
promoter or a deletion in the NPR-A gene promoter are
associated with patients with hypertension and cardiac
hypertrophy, suggesting that defects in the ANP pathway
may contribute to hypertensive disease.29,30 Recently, two
nonsynonymous and nonconservative SNPs (T555I and
Q568P) are found in the human corin gene.31 These two
SNPs are in complete linkage disequilibrium in the popula-
tion and, as a result, are colocalized in a minor allele (I555/
P568). Epidemiological studies of large population-based
cohorts, including the Dallas Heart Study, the Multi-Ethnic
Study of Atherosclerosis (MESA), and the Chicago Genetics
of Hypertension Study, have shown that the minor corin
I555/P568 allele is more common in African Americans than
in Caucasians (B12 vs o0.2% carrying one or more copies
of the allele) and associated with an increased risk for
hypertension.31
In addition, the I555/P568 corin minor allele was reported
to be associated with an enhanced concentric cardiac
hypertrophy in response to high systolic blood pressure in
African Americans from the Dallas Heart and MESA
cohorts.32 Patients with this corin allele had a greater
left ventricular mass compared to that of control patients
with a wild-type allele but similar systolic blood pressure. The
data linking the corin gene variant to myocardial pathology
in patients is intriguing.33 Earlier animal studies have
indicated that the ANP pathway has a local anti-hypertrophy
function in the heart, which is independent of its systemic
action on blood pressure.34 Consistently, we also showed
that corin-null mice developed cardiac hypertrophy.22 These
data suggest that corin deficiency may contribute to
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hypertension and heart failure in African Americans, a
population known for its high prevalence of these cardio-
vascular diseases.
UNANSWERED QUESTIONS
For more than a quarter century, significant knowledge has
been gained for the natriuretic peptides and their biological
function and therapeutic potential.35 And yet, much more
remains to be learned. For example, both ANP and BNP are
thought to bind NPR-A, but this concept may not be
satisfactory. The affinity of ANP binding to the receptor was
shown to be B10 times higher than that for BNP binding.36
How, then, could BNP bind to the receptor in the presence of
similar levels of ANP? More importantly, ANP- and
BNP-knockout mice have very different phenotypes.27,37 If
these peptides can substitute each other for the same
receptor, why do ANP- and BNP-knockout mice have a
phenotype at all? Some studies suggest that there may be
another receptor for BNP but its identity remains un-
known.38 As ANP and BNP are being developed to treat
patients with heart failure,5 answers to these questions will be
critical to understand the therapeutic efficacy and unwanted
side effects of these peptides.
The discovery of corin and characterization of the
hypertensive phenotype in corin-null mice highlight the
importance of natriuretic peptide processing and point to a
long-neglected area in this field. For years, radioimmuno-
assay and enzyme-linked immunosorbent assay are used to
measure ANP and BNP in a variety of clinical and
experimental settings. The antibodies used in these assays
may not distinguish processed from unprocessed natriuretic
peptides. For example, antibodies bind to ANP may also
recognize pro-ANP. As a result, it is not clear which
molecular forms, that is, ANP, pro-ANP, or both, are
measured in these assays. Similar situation applies to BNP
and pro-BNP assays. As plasma BNP is used as a diagnostic
test for heart failure,39 this issue is of clinical importance.
Corin is a newly discovered enzyme. We are only at the
beginning toward understanding its biology.40 Many
questions remain regarding corin function and regulation
under physiological and pathological conditions. In animal
models of heart failure, for example, corin mRNA expression
was shown to be upregulated in the ventricle41,42 but
downregulated in the atrium.43 It appears that corin
regulation is a part of the pathological process during heart
failure but the results need to be verified in samples from
patients with heart failure. Further studies of corin should
provide new insights into the natriuretic peptide system and
may help to design new strategies to diagnose and treat
hypertension and heart disease.
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